Fred Alger Management’s Standard BioTools LAB Stock Holding History

Fred Alger Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-195,490	Closed	-$313K	–	546
2022 Q2	$313K	Sell	195,490 -204,798	-51%	-$507K	﹤0.01%	415
2022 Q1	$1.44M	Buy	+400,288	New	+$1.38M	﹤0.01%	360
2018 Q4	–	Sell	-38,000	Closed	-$285K	–	540
2018 Q3	$285K	Buy	+38,000	New	+$270K	﹤0.01%	380

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JCP

Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Fred Alger Management's LAB Position: Q3 2022 in Review

Fred Alger Management sold out of Standard BioTools (LAB) in Q3 2022, closing a stake of 195,490 shares — an estimated $313K sold.

Fred Alger Management first reported a position in LAB in Q3 2018 and held it in 3 quarters. The position peaked at $1.44M in Q1 2022. 65 funds tracked by Wall St. Rank hold LAB as of Q3 2022.

Fred Alger Management reported no remaining Standard BioTools position as of Q3 2022 after selling out during the quarter.
Fred Alger Management sold 195,490 Standard BioTools shares in Q3 2022, an estimated $313K.
Fred Alger Management first reported a position in Standard BioTools in Q3 2018 and held it in 3 quarters.
Fred Alger Management's Standard BioTools position peaked at $1.44M in Q1 2022.
65 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2022.

Based on Fred Alger Management's 13F filing for Q3 2022, filed 15 Nov 2022.